Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats

Pharmazie

Volumn 67, Issue 5, 2012, Pages 384-388

  Mori, N ^a   Iwamoto, H ^a   Yokooji, T ^a   Murakami, Teruo ^a  

^a HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; HYDROXYPROPYLMETHYLCELLULOSE; QUINIDINE; RANITIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG RETENTION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DUODENUM; ILEUM; INTESTINE ABSORPTION; JEJUNUM; LIPOPHILICITY; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; POWDER; PROTEIN EXPRESSION; RAT; SOLUTION AND SOLUBILITY; STOMACH PH;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXTRANS; FLUORESCEIN-5-ISOTHIOCYANATE; GASTRIC ACID; HYDROGEN-ION CONCENTRATION; INDICATORS AND REAGENTS; INTESTINAL ABSORPTION; INTESTINES; MALE; MOLECULAR WEIGHT; P-GLYCOPROTEIN; POWDERS; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84862333933     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1700     Document Type: Article

References (30)

1. Adachi Y, Suzuki H, Sugiyama Y (2003) Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm Res 20: 1163-1169.
2. AlHusban FA, El-Shaer AM, Jones RJ, Mohammed AR (2010) Recent patents and trends in orally disintegrating tablets. Recent Pat Drug Deliv Formul 4: 178-197.
3. Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420.
4. Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21: 25-51.
5. Chianale J, Vollrath V, Wielandt AM, Miranda S, Gonzalez R, Fresno AM, Quintana C, Gonzalez S, Andrade L, Guzman S (1995) Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal axis of the mouse intestine. Biochim Biophys Acta 1264: 369-376.
6. Dahan A, Sabit H, Amidon GL (2009) Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 37: 2028-2036.
7. Douroumis D (2011) Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin Drug Deliv 8: 665-675.
8. Emi Y, Tsunashima D, Ogawara K, Higaki K, Kimura T (1998) Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J Pharm Sci 87: 295-299.
9. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C (1996) Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 118: 1841-1847.
10. Goel H, Rai P, Rana V, Tiwary AK (2008) Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul 2: 258-274.
11. Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, MacLaughlin DS, Smith TW, Koch-Weser J (1977) Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 202: 365-378.
12. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104: 147-153.
13. Ho GT, Moodie FM, Satsangi J (2003) Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52: 759-766.
14. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y (1997) P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283: 574-580.
15. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin- Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62: 248-260.
16. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K (2000) Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 68: 98-103.
17. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55: 425-461.
18. Mori N, Yokooji T, Murakami T (2008a) Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats. Pharmazie 63: 241-244.
19. Mori N, Yokooji T, Kamio Y, Murakami T (2008b) Characterization of intestinal absorption of mizoribine mediated byconcentrative nucleoside transporters in rats. Eur J Pharmacol 586: 52-58.
20. Mouly S, Paine MF (2003) P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20: 1595-1599.
21. Murakami T, Takano M (2008) Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4: 923-939.
22. Murakami T, Yokooji T, Mori N (2010) Study on absorption sites of quinidine and methotrexate in rat intestine. Pharmazie 65: 440-447.
23. Nishiura A, Higashi J, Murakami T, Higashi Y, Yata N (1986) A possible contribution of phospholipids in tissue distribution of quinidine in rats. J Pharmacobiodyn 9: 819-828.
24. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283: 1552-1562.
25. Sakaeda T, Nakamura T, Okumura T, Tochio S, Nagata T (2002) Dissolution properties of hydroxypropylmethylcellulose (HPMC) capsules. Jpn J Pharm Health Care Sci 28: 594-598.
26. Shiga A, Sasaki T, Horii, N (1987) Correlations among pH and Mg, Ca, P, Na, K, Cl- and HCO3- contents of digesta in the gastro-intestinal tract of rats. Jpn J Vet Sci 49: 973-979.
27. Strickley RG, Iwata Q, Wu S, Dahl TC (2008) Pediatric drugs-a review of commercially available oral formulations. J Pharm Sci 97: 1731-1774.
28. Takano M, Yumoto R, Murakami T (2006) Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 109: 137-1361.
29. Wu CY, Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22: 11-23.
30. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M (1999) Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289: 149-155.